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In 2001, Schalkwijk et al. described, in eight patients
from five families, a new autosomal recessive type of
Ehlers-Danlos syndrome (EDS), caused by mutations in the
tenascin-X (TNXB) gene and leading to a total deficiency
of tenascin-X.1 Since then no other patients with tenascin-X
deficiency have been published; apparently it is a rare
type of EDS. This new type of EDS can be differentiated
from the classic type, which it resembles most, by its
mode of inheritance (autosomal recessive vs autosomal
dominant) and the absence of abnormal scarring, which
is one of the key features in the classic type of EDS.
Remarkably, this new type is associated with congenital
adrenal hyperplasia when it is due to a deletion encom-
passing the CYP21 gene.1,2
EDS consists of a group of inherited connective tissue
disorders, mainly characterised by generalised joint
hypermobility (= Beighton hypermobility score of 5 or more),
skin hyperextensibility (measured at the volar side of the
underarm and/or at the flexed elbow), easy bruising and
skin fragility (ranging from easy tearing after minor trauma
to thin, broad scars and soft and velvety skin). It exhibits
an enormous clinical and genetic heterogeneity. The
monography by Beighton was the first comprehensive
study of the syndrome and is still worth reading.3 In the
latest classification six types are recognised (see table 1).4
EDS is not rare with an estimated prevalence of 1/5000.
More than 90% of patients have either the classic or the
hypermobility type.5
The classic type of EDS is characterised by all the main
EDS features, namely hyperextensibility of the skin, broad
and thin scarring (‘cigarette-paper’ scars), generalised joint
hypermobility and easy bruising. Aortic dilatation and dis-
section is a rare complication of this EDS type. Well-known
complications are recurrent (sub)luxations with chronic
joint pain and early osteoarthrosis, hiatus hernia, anal
© 2004 Van Zuiden Communications B.V. All rights reserved.
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Table 1
Villefranche classification of Ehlers-Danlos syndrome
NEW NAME OLD NAME INHERITANCE MUTATED GENES
Classic type Gravis = type I AD COL5A1, COL5A2
Mitis = type II
Hypermobility type Hypermobile = type III AD Unknown; ?TNXB?
Vascular type Arterial-ecchymotic = type IV AD COL3A1
Kyphoscoliosis type Ocular-scoliotic = type VI AR Lysyl-hydroxylase
Arthrochalasia type Arthrochalasis multiplex congenita AD COL1A1, COL1A2
= type VIIA and type VIIB
Dermatosparaxis type Dermatosparaxis = type VIIC AR Procollagen, N-peptidase
AD = autosomal dominant, AR = autosomal recessive.
prolapse, cervix uteri insufficiency with premature labour as
a result and cicatrical hernia. There is a large interfamilial
and intrafamilial clinical variability. The male-to-female ratio
is almost equal to one. In about 50% of cases a mutation
can be detected in cultured fibroblasts in the COL5A1 or
COL5A2 genes. 
The hypermobility type of EDS has generalised joint hyper-
mobility and mildly hyperextensible and/or soft and velvety
skin as its main features. The main problem is the joint
hypermobility with its sequelae, recurrent (sub)luxations
of mainly shoulder, patella and jaw, chronic joint pain which
can be severe and invalidating, and early arthrosis.
Complications related to internal organs are extremely rare.
It should be distinguished from the benign joint hyper-
mobility syndrome (BJHS), which lacks the skin symptoms
of EDS. However, there is much debate whether BJHS
and the hypermobility type of EDS are not one and the
same disorder.6 Personally, I adhere to the strict definition
of BJHS, namely generalised joint hypermobility with
Beighton scores >5, joint pain during a longer period in
several joints and absence of skin features. Recently, Zweers
et al. reported their tenascin-X findings in two groups of
patients.7 First, the haploinsufficient family members
(n=20, mainly siblings, children, parents) of their patients
with absent tenascin-X due to homozygous or compound
heterozygous TNXB mutations: in this group, nine out of
14 women – and none of the six males – showed genera-
lised joint hypermobility and four of these nine women
also had a velvety skin. The second group consisted of 80
hypermobility type EDS patients, diagnosed by a medical
specialist and recruited through the Dutch EDS patient
organisation. In six (7.5%; all females) of these, tenascin-X
haploinsufficiency was detected. Four of these six patients
were examined: two had Beighton scores <5 and no abnor-
mal skin, while of the two with Beighton scores >5, one had
normal skin. What does this tell us? Firstly, that probably
quite a few of the 80 hypermobility-type EDS patients do
not have the hypermobility type of EDS nor the strictly
defined BJHS, secondly, that a better controlled study is
needed to clarify the role of tenascin-X in hypermobility
disorders, and thirdly that most likely skin extensibility and
joint mobility is the end result of the involvement of many
genes and exogeneous factors (‘multifactorial’). This is
illustrated in among other ways by the fact that haploinsuf-
ficiency for tenascin-X does exist without phenotype, for a
presumed autosomal dominant disorder far too many
patients are sporadic (= not familial) and almost all patients
with the hypermobility type of EDS and BJHS are female.
The vascular type of EDS is more rare than the two previous
ones but it is the most serious and life-threatening of all.
Thin skin due to lack of subcutaneous fat with prominent
venous pattern and a peculiar face and easy bruising are
hallmarks as well the easy rupturing of internal organs as
the large arteries, large intestines and uterus. Pregnant
women with the vascular type of EDS are at an increased
risk for severe complications. It is caused by mutations in
COL3A1 gene (cultured fibroblasts), which are detectable
in nearly all patients. 
The other three types are even rarer and will not be dis-
cussed in detail. Apart from these six EDS types and the
new tenascin-X deficient type, there are more poorly defined
EDS types and single family ‘types’.4 From clinical practice
it is known that not every patient with an EDS phenotype
can be classified in one of the well-defined types. 
EDS is diagnosed and classified on the basis of history,
family history and physical examination with laboratory
confirmation when possible and indicated, at the protein
level (tenascin-X in serum, collagen 1, 3 and 5 in fibroblasts)
and/or at the molecular level (see text and table 1). 
Interestingly, some often heard complaints are not readily
found in textbooks on EDS: easy fatigue is one of these as
is the ineffectiveness of local anaesthesia; the former is
particularly clinically important and often distressing.
Single reports on EDS patients with various clotting
abnormalities (for example von Willebrand disease, factor
IX deficiency, factor XIII deficiency, platelet release defect,
fibronectin deficiency) have been published, but the cause
of the easy bruising is much more likely to be due to vessel
wall fragility than to a coagulation defect.5
Management of EDS is largely supportive (e.g. physio-
therapy, ergotherapy, rehabilitation) and preventive (e.g.
surgical precautions, avoiding certain professions and sports,
avoiding overweight); it is rarely surgical (e.g. arthrodesis).
Genetic counselling is part of the management. 
Differential diagnosis of EDS includes other connective
tissue disorders such as Marfan’s syndrome, cutis laxa and
osteogenesis imperfecta, but also a host of other diagnoses
depending on the presenting complaint/symptom. Since
it is also of great importance for the internist to recognise
EDS in order to start timely management and to avoid
unnecessary investigations, it is therefore wise of the editors
of the Netherlands Journal of Medicine to publish the paper
by Peeters et al.,8 not so much to draw attention to this
rare type of EDS, but more to EDS in general.
N O T E
There is an active Dutch patient organisation (Vereniging
van Ehlers-Danlos patienten, www.ehlers-danlos.nl). In the
Netherlands, the molecular and protein diagnostics of EDS
(for types see table 1) are performed at the VU University
Medical Center, Department of Clinical and Human
Genetics, Laboratory for DNA and Protein Diagnostics,
Amsterdam, head Dr G.Pals.
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A B S T R A C T
Recent trials investigating the effects of strict glucose regu-
lation in critically ill patients have shown impressive
reductions in morbidity and mortality. Although the litera-
ture focuses on the possible toxic effects of high blood
glucose levels, the underlying mechanism for this improve-
ment is unclear. We hypothesise that strict glucose regulation
results in modulation of cytokine production, leading to a
shift towards a more anti-inflammatory pattern. This shift
in the cytokine balance accounts for the reduction in
morbidity and mortality. 
To support our hypothesis, effects of glucose and insulin on
cytokine release and effects of glucose, insulin, and cytokines
on host defence, cardiac function and coagulation will be
reviewed.
I N T R O D U C T I O N
Diabetic patients are at risk for cardiovascular and various
infectious diseases while infections will often run a compli-
cated course.1 The reason for this increased susceptibility to
infections may be an impaired immune defence, microvas-
cular and macrovascular comorbidity, the relative high
number of medical interventions or – viewed from the
microbial site – an altered adherence of micro-organisms
to human cells under hyperglycaemic conditions.2
Reportedly, postoperative hyperglycaemia is an independent
risk factor for the development of infectious complications.4
A large recent study by Van den Berghe et al.4 in critically
ill patients showed that maintenance of blood glucose
levels between 4.4 and 6.1 mmol/l results in a 42%
reduction in mortality compared with conventional treat-
ment aimed at blood glucose levels between 9.9 and 11.1
mmol/l. Patients with multiple-organ failure and a proven
septic focus demonstrated the greatest improvement with
intensive insulin therapy. In addition, in patients with acute
myocardial infarction maintenance of blood glucose levels
below 11.9 mmol/l has been shown to increase the success
rate of thrombolysis,5 preserves myocardial function,6 and
improves long-term outcome.7,8
How the strict control of blood glucose reduces morbidity
and mortality is not known, but it is thought that the mech-
anism may be related either to a direct effect of normal-
isation of hyperglycaemia or to the concomitant higher
insulin levels.
There is a striking similarity between the effects of high
glucose levels on host defence, cardiac function and
coagulation and the observation of elevated systemic
levels of proinflammatory cytokines during critical illness.
Cytokines, low-molecular-weight proteins produced by
various immune-competent cells, have important modu-
lating effects on the immune response. Cytokines have
autocrine, paracrine and endocrine effects.9 Whereas the
local autocrine and paracrine effects may be beneficial in
M A Y  2 0 0 4 ,  V O L .  6 2 ,  N O .  5
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containing the infection or tissue damage,10-13 the systemic
endocrine effects of the so-called proinflammatory cytokines,
such as tumour necrosis factor- (TNF) and interleukin-1
(IL-1), are considered to be deleterious. During the normal
response to infections or to noninfectious stressors, the
tailored and balanced production of proinflammatory
cytokines, aiming at stimulation of the innate immune
response, and anti-inflammatory cytokines, curtailing the
potential deleterious effects of inflammation, ensures a
favourable outcome. However, when this balance is distorted
towards an insufficient control of the infection or towards
a dominant systemic proinflammatory status designated as
‘lethal cytokinaemia’,14 the condition of the patient deteri-
orates and shock or death may develop. There are indica-
tions that glucose levels influence the type and quantity
of cytokine release.
In the present article, we hypothesise that a better control
of hyperglycaemia shifts the systemic cytokine profile
towards a more anti-inflammatory balance resulting in a
decreased morbidity and mortality of critically ill patients.
This hypothesis is based on and derived from various in
vitro and in vivo studies on the effect of glucose and
insulin on immune functions, cardiac performance and
coagulation. 
T H E  H Y P O T H E S I S  
Normalisation of hyperglycaemia in acute and critically 
ill patients will shift the cytokine profile from a systemic
proinflammatory status to a more balanced anti-inflam-
matory condition. By this mechanism, normoglycaemia
improves and restores host defence, haemodynamics and
coagulation abnormalities and decreases morbidity and
mortality.
E F F E C T S  O F  G L U C O S E  A N D  
I N S U L I N  O N  H O S T  D E F E N C E ,  R O L E
O F  C Y T O K I N E S
While glucose is freely permeable across the cell membrane
of leucocytes in diabetic patients, these cells display a
decreased rate of glycolysis15 and an increased glucose
consumption after the addition of small amounts of
insulin.16 In diabetic patients, a variety of abnormalities
in neutrophil function have been observed such as
decreased chemotaxis, increased adherence to endothelium,
decreased phagocytosis, decreased bacterial killing and
overproduction of free radicals. These defects may result
from short-term metabolic effects of hyperglycaemia and
(relative) insulin deficiency or from long-term effects
such as increased glycation. 
It has been shown in vitro that D-glucose and insulin,
alone or in combination, improve chemotaxis of neutro-
phils from healthy humans.17,18 D-glucose alone is able to
increase neutrophil locomotion in a dose-dependent
fashion. However, as studied in vivo, N-formyl-methionyl-
leucyl-phenylalanine (fMLP) and complement-induced
chemotaxis is significantly lower in diabetic patients than
in healthy controls, probably because of the increased
expression of the adhesion promoting 2-integrins CD11b
and CD11c.19 Because in addition, glucose increases the
expression in vitro of adhesion molecules on endothelium
such as E-selectin, intracellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1),20
hyperglycaemia will promote the binding of leucocytes to
endothelium.21 Recently, it was demonstrated that KATP
channel blockade with glibenclamide inhibited fMLP and
lipopolysaccharide-induced neutrophil activation and
migration in vitro and in vivo,22 suggesting that, independent
of glucose and insulin, treatment of type 2 diabetic patients
with glibenclamide could be detrimental to immune
function. In type 2 diabetic patients circulating levels of
cytokines and adhesion molecules are increased following
a meal rich in carbohydrates.23 This effect was inhibited by
pretreatment with high doses of vitamin C and E, indicating
that an oxidative mechanism mediates this effect.
Phagocytosis is impaired in diabetes.24 This impairment
is at least partly mediated by elevated levels of cytosolic
calcium. In a prospective cohort study of patients with
type 2 diabetes, higher fasting glucose levels were cor-
related with higher cytosolic calcium levels in neutrophils
and with decreased phagocytic activity.25 In type 2 diabetes
mellitus this impaired phagocytic activity can be restored
by glibenclamide therapy, either as a result of the gliben-
clamide-stimulated insulin production or decreased
serum glucose levels. In diabetes, ingested bacteria seem
to be protected from killing by intracellular bactericidal
mechanisms.26 Under hyperglycaemic conditions, proteins
may be glycated resulting in the formation of so-called
advanced glycation end products (AGEs). Recent studies
have shown that these AGEs can bind to the corresponding
receptor on neutrophils and impair intracellular bacterial
killing.18 Delamaire et al. reported that, although elevated
in the unstimulated state, bactericidal activity of stimulated
neutrophils was significantly depressed in diabetic
patients.19
Neutrophils from diabetic patients show increased levels
of basal free radical release as measured by chemolumi-
nescence. This increased free radical production, in com-
bination with increased adhesion, may induce local
lesions in the vascular endothelium.19
Although all these defects in leucocyte function have been
reported in diabetic patients, the exact mechanism and
the effects of short-term glucose control are still not clear.
We speculate that high glucose concentrations influence
host defence by the modulation of cytokine synthesis.
Pickkers, et al. Favourable effects of strict glucose regulation.
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This mechanism is sustained by a recent report by
Morohoshi et al. that showed a glucose-dependent increase
in basal TNF and IL-6 production in human monocytes
in vitro.27 Similarly, studies by our group demonstrated
a glucose-dependent increased production of TNF by
peripheral blood cells in vitro after stimulation with
lipopolysaccharide, whereas glucose does not influence the
production of the anti-inflammatory cytokine IL-10.28 We
also demonstrated that in vivo induced hypoglycaemia in
hypoglycaemic human clamp models (achieved glucose
levels 5.0, 3.5, and 2.5 mmol/l) resulted in a down-modula-
tion of LPS-induced TNF synthesis.29 Together, these
studies strongly suggest that glucose may stimulate the
production of proinflammatory cytokines such as TNF
and IL-6, with no effect on the anti-inflammatory cytokine
IL-10. Therefore, normalisation of hyperglycaemia may
result in a shift of cytokine production towards a more
balanced anti-inflammatory profile.
In addition to the effect of glucose on the production of
pro- and anti-inflammatory cytokines, several effects of
insulin on cytokine production have been shown.30 Satomi
et al. demonstrated that insulin blocks TNF production
by peritoneal macrophages.31 Insulin has been shown to
have a potential anti-inflammatory activity, since it inhibits
the expression of the proinflammatory adhesion molecule
ICAM-1 by endothelial cells32 and increases the expression
of the mRNA for macrophage migration inhibitory factor.33
Rats treated with recombinant TNF have a significant
decrease in food intake, nitrogen balance and body weight
compared with saline-treated control rats.34 Concurrent
insulin administration reversed all these changes. Five days
of TNF treatment caused severe interstitial pneumonitis,
periportal hepatitis and increased wet organ weight of heart,
lung, kidney and spleen. Concurrent insulin treatment led
to near total reversal of these pathological changes. However,
as systemic insulin administration results in lower glucose
concentrations, the observed effects cannot be attributed
to insulin per se.
Of the several questions that can be addressed, perhaps
the most intriguing is how glucose mediates the TNF
production. A possible explanation involves nuclear factor
kappa-B (NFB). The inducible transcription factor NFB
was discovered in 198635 and is present in the cytoplasm
of many different cell types, such as leucocytes, endothelial
and epithelial cells. Activation of this protein initiates its
translocation into the nucleus where it binds to specific
sequences in the promotor regions of target genes. This will
result in an increased rate of transcription of the gene, more
messenger RNA (mRNA) and more protein. NFB plays
a pivotal role in the regulation of the synthesis of various
proinflammatory proteins, including cytokines, cell-adhesion
molecules and inducible nitric oxide synthase. In sepsis,
NFB expression is upregulated and a persistently increased
expression correlates with nonsurvival.36 The production
of NFB is stimulated by lipopolysaccharide (LPS), TNF,
IL-1, and phorbol 12-myristate 13-acetate. The anti-inflam-
matory cytokine IL-10 inhibits NFB formation. In type 2
diabetes it has been shown that IL-1 inhibits pancreatic
 cell function and promotes Fas-triggered apoptosis in part
by activating NFB.37 This suggests that an inflammatory
process is involved in the pathogenesis of glucotoxicity in
type 2 diabetes, which is mediated by NFB.
In Gram-negative sepsis, LPS or endotoxin binds to several
receptors of which CD14 is one of the most extensively
studied. After binding to LPS, this receptor forms a complex
with the toll-like receptor 4 (TLR4).38 Activation of TLR4
results in the activation of the NFB signalling pathway and
subsequently to the production of cytokines such as TNF,
IL-1, IL-2, IL-6, IL-8, and IL-12, and interferon- (IFN).
TNF, in a positive regulatory loop, can lead to further
excessive activation of NFB and to cytokine-mediated
effects such as endothelial cell injury, disseminated
intravascular coagulation, septic shock or death.
Hyperglycaemia rapidly induces activation of NFB within
hours of its onset.39 NFB activation induced by elevated
concentrations of carbohydrates is associated with increased
monocyte adhesion to endothelial cells and the generation
of oxygen radicals.40 Adherence of leucocytes to human
umbilical vein endothelial cells was strongly augmented
by elevation of the glucose concentration in the perfusate
from 5 mmol/l to 30 mmol/l. In the same experiment it
was shown that this effect was paralleled by an intense
NFB activation.20 So, direct effects of glucose on NFB
activation may well be the initiator of the deleterious effects
of increased systemic cytokine production. However, as
NFB is also involved in the stimulation of some anti-
inflammatory cytokines, more subtle stimulation of
intracellular pathways is likely to be involved. Oxidative
stress-mediated cellular damage may be involved in
hyperglycaemia-induced activation (reviewed in),41 as was
shown by treating diabetic patients with antioxidants that
significantly suppressed NFB activation. By inhibiting
NFB activation, transcription of genes under NFB control,
such as adhesion molecules and cytokines, is prevented.
Macrophage migration inhibitory factor (MIF) is a pro-
inflammatory chemokine produced primarily by the anterior
pituitary gland.42 LPS-induced secretion of MIF from the
pituitary gland and from circulating/tissue resident
monocyte/macrophages is thought to play an important
role in the pathogenesis of endotoxaemia and sepsis and
might be an integral part of the host’s systemic stress
response. In mice that received endotoxin, there was a
dramatic fall in the pituitary content of MIF, associated
with a concomitant increase in plasma levels of MIF.43,44
In vivo studies in rats have shown that MIF protein is
released from the pituitary, adrenal gland, liver, spleen,
lung, kidney and skin within six hours of LPS injection.45
Upon release, MIF is directly proinflammatory by activating
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or promoting cytokine expression (TNF;46,47 IL-1, IL-2;48
IL-6;46,49 IL-8;50 and interferon-48,51). From this data it is
stated that ‘MIF’s position within the cytokine cascade is
to act in concert with glucocorticoids to control the set
point of the immune and inflammatory response’.42
Similarly to TNF, high MIF levels are closely linked with
poor outcome in patients with systemic inflammatory
response syndrome (SIRS).52 Again, there is a link with
glucose metabolism: the insulin-secreting  cells in the
pancreas express MIF, and both MIF and insulin colo-
calise by immuno-cytochemistry within the secretory
granules.53 MIF is secreted in response to glucose stimu-
lation in a time- and concentration-dependent fashion. In
turn, exogenously administered MIF potentiates insulin
release. MIF thus plays an important regulatory role in
carbohydrate metabolism and its secretion is regulated
by glucose. Through effects on MIF, strict glucose regula-
tion could influence the pro-/anti-inflammatory cytokine
balance.
E F F E C T S  O F  G L U C O S E  A N D  I N S U L I N
O N  C A R D I A C  F U N C T I O N ,  R O L E  O F
C Y T O K I N E S  
Inflammation plays a pathogenic role in the development of
acute coronary syndromes.54,55 Increased levels of TNF,
IL-1, IL-6, IL-8 and MIF have been observed after acute
myocardial infarction56,57 and postinfarction IL-6 levels
correlate significantly with the extent of myocardial tissue
damage.58 TNF production forms part of an important
intrinsic myocardial stress response system to injury.
Within the myocardium TNF is not only confined to the
infarct and peri-infarct zone, but is also expressed in cardiac
myocytes of the contralateral myocardium.59 As can be
concluded from a study in mice, TNF has, apart from its
pathogenic role in the acute inflammatory response during
the acute ischaemia, also a protective role in limiting the
ischaemia-induced apoptosis.60 Several studies have sug-
gested that treatment of acute myocardial infarction with
infusions of glucose, insulin and potassium is beneficial.61-63
It remains unclear whether normalisation of hyperglycaemia
or the higher insulin levels account for these beneficial
effects. Insulin has been shown to attenuate infarct size
in the isolated rat heart, independent of the presence of
glucose,64 and it was also demonstrated that infarct size
was linearly related to blood glucose concentration during
acute hyperglycaemia independent of insulin concentration
in dogs.65 The DIGAMI study was initiated to test the
hypothesis that rapid improvement of metabolic control in
diabetic patients with acute myocardial infarction improves
short- and long-term outcome.7,8 Patients were randomised
to insulin-glucose infusion followed by multidose subcuta-
neous insulin therapy or conventional therapy. In the
intensive therapy group mortality rate was reduced by
30% after one year. This effect is most likely the result of
better local metabolic control in the myocardium or, in
accordance to the presently presented hypothesis, to an
altered cytokine-mediated inflammatory response. 
E F F E C T S  O F  G L U C O S E  A N D  I N S U L I N
O N  C O A G U L A T I O N ,  R O L E  O F
C Y T O K I N E S  
In critically ill patients, derangement of the coagulation
system comprises enhanced activation of coagulation,
depression of inhibitory mechanisms of coagulation, and
inhibition of fibrinolysis. An antifibrinolytic endothelium
phenotype is associated with multiorgan failure and
mortality.66 Derangement of the coagulation system
appears to be mediated by various cytokines and may
contribute to the pathogenesis of multiple organ failure.
In human umbilical vein endothelial cells, TNF alters
the coagulant activity by stimulation of the production
and surface expression of tissue factor and by inhibition
Pickkers, et al. Favourable effects of strict glucose regulation.
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Figure 1
Representation of the hypothesis. Correction of high
glucose concentration results in less NFB activation and
down-modulation of TNF production, resulting in less
spill-over to the systemic circulation. The production of
the anti-inflammatory cytokine IL-10 is not influenced by
glucose. This leads to a new pro- and anti-inflammatory
cytokine balance with favourable effects on host defence,
myocardial function, and coagulation. In the presence of
little experimental evidence, the possible role of insulin
remains questionable.
Table 1
Summary of the effects of hyperglycaemia (compared
with normoglycaemia)
EFFECTS ON HOST DEFENCE
NfB induction
Production of proinflammatory cytokines, MIF
Production of anti-inflammatory cytokines =
Expression of adhesion molecules
Binding of leucocytes to endothelium
Phagocytic activation
Intracellular bacterial killing
EFFECTS ON CARDIAC FUNCTION
Infarct size
Postinfarction mortality
EFFECTS ON COAGULATION
PA-1 concentration
Thromboxane concentration
Platelet activity
of anticoagulant mechanism, particularly the activation of
the protein C system.67,68 In healthy human volunteers,
infusion of TNF activates the coagulation system identi-
cally to what is seen in septic patients or in volunteers after
endotoxin infusion,69,70 and this activation of the coagula-
tion seems to be, at least initially, dependent on activation
of the extrinsic pathway of blood coagulation.71 In septic
patients, the fibrinolytic system becomes initially activated
and subsequently inhibited.72 Blockade of TNF with
monoclonal antibodies inhibits the fibrinolytic response
upon the administration of endotoxin.73-75 The mechanisms
underlying the effects of TNF on the fibrinolytic system
are not completely clear. It is suggested that the rapid
effects are not due to enhanced gene expression observed
in vitro,76,77 but to release of stored plasminogen activators
probably from the vascular endothelium and endotoxin-
activated platelets.
The level of plasminogen activator inhibitor type I (PAI),
an inhibitor of fibrinolysis, is higher in diabetic patients
as compared with nondiabetics, and associated with the
occurrence of myocardial infarction.78 Systemic insulin
treatment decreases the plasma activity of PAI in type 2
diabetic patients.79 Human administration of recombinant
IL-6, another proinflammatory cytokine, resulted in an
increased thrombin generation80 and antibodies directed
against IL-6 are able to completely abolish the endotoxin-
induced activation of coagulation in chimpanzees.75 Also,
diabetes has been associated with platelet hyperactivity
to agonists in vitro, and alterations in a number of
mechanisms involved in platelet activation occur in
diabetic platelets. These alterations include increased
presence of glycoprotein receptors for agonists and adhesive
proteins on the platelet surface, increased fibrinogen bind-
ing, decreased membrane fluidity, enhanced arachidonate
pathway activation with increased thromboxane A2 form-
ation, and increased phosphoinositide turnover leading to
increased inositol triphosphate production, calcium mobil-
isation, and protein phosphorylation.81 Tight glycaemic
control with insulin therapy reduces the excretion levels
of a thromboxane metabolite by approximately 50%.82
Again, the mechanism responsible for this effect is
unclear.83 In accordance with our hypothesis, the effect of
systemic insulin treatment could by explained by better
glucose control, subsequent inhibition of proinflammatory
cytokines, resulting in a reduced cytokine-induced pro-
coagulatory state. 
Recently, it was shown that suppletion of the anticoagulatory
protein recombinant activated protein C (aPC) reduces the
mortality in critically ill patients.84 Apart from the insulin
study by Van de Berghe et al.4 this is the only immune-
modulatory strategy so far that has proven to be efficacious.
The effects of aPC, however, appear to involve more than
its antithrombotic activity. Similar to one of the effects of
strict glucose control, aPC influences translocation of NFB
and cytokine production in an anti-inflammatory way.85
Normalisation of hyperglycaemia may therefore be bene-
ficial either directly or by a restoration of the cytokine
balance, through a positive effect on the immune function,
through the improvement of haemodynamics or through
a decrease of the undesirable procoagulatory state.
C O N C L U S I O N  A N D  F U T U R E  
D I R E C T I O N S
Strict control of plasma glucose in acute and critically ill dia-
betic and nondiabetic patients has been shown to improve
outcome in several clinical settings. The mechanism of
action of these beneficial effects is not known, although
in critically ill patients, the control of glucose levels rather
than the absolute levels of insulin appear to account for
the positive effects of strict regulation.86 From the literature
and our own studies it can be concluded that hypergly-
caemia augments the production of proinflammatory
cytokines. There is a striking similarity between the effects
of glucose on host defence, cardiac performance and
coagulation and the proinflammatory cytokine status
associated with critical illness. Although in acute or critically
ill patients various mutually dependent overlapping and
redundant pathophysiological mechanisms are known to
influence the clinical course in a complex fashion, we claim
that the modulation of cytokines explains the beneficial
effect of a more strict glycaemic control. Cognisant the
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beneficial local autocrine and paracrine action and the
potentially deleterious systemic endocrine effect of pro-
inflammatory cytokines, we suggest that future studies to
test this hypothesis encompass local and systemic cytokine
production. Further understanding of the mechanism by
which intensive therapy with insulin reduces morbidity and
mortality in acute and critically ill patients will probably
take place at the crossroads of metabolic control, immune
response, cardiac performance and coagulation.
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Advertentie Thyrax
A B S T R A C T
The arterial baroreflex buffers abrupt transients of blood
pressure and prevents pressure from rising or falling
excessively. In experimental animals, baroreceptor denerva-
tion results in temporary or permanent increases in blood
pressure level and variability, depending on the extent of
denervation. In humans, the clinical syndrome of
baroreflex failure may arise from denervation of carotid
baroreceptors following carotid body tumour resection,
carotid artery surgery, neck irradiation and neck trauma.
The syndrome is characterised by acute malignant hyper-
tension and tachycardia followed by labile hypertension and
hypotension. Baroreflex failure can be a cause of hyper-
tension and should also be considered in the differential
diagnosis of pheochromocytoma. Patients with suspected
baroreflex failure should be referred to specialised centres
for diagnostic testing and treatment. 
B A R O R E C E P T O R S
In the late 1920s, Hering and Koch were the first to recog-
nise the reflex nature of changes in heart rate and blood
pressure evoked by external massage of the neck. The
afferents were tracked as nerve endings at the carotid
bifurcation.1,2 The arterial baroreflex buffers abrupt transients
of blood pressure and originates from stretch sensitive
receptors in the arterial wall of the carotid sinus and the
aortic arch and large vessels of the thorax.3,4 Afferent fibres
from carotid sinus baroreceptors join the glossopharyngeal
nerve (ninth cranial nerve) and project to the nucleus
tractus solitarii in the dorsal medulla, which in turn projects
to efferent cardiovascular neurones in the medulla. In
addition to carotid baroreceptors, stretch-sensitive baro-
receptors are also located in the aortic arch, heart and
large pulmonary vessels. The extra-carotid baroreceptors
transmit their afferent information along with the vagal
nerves to the same brain stem nuclei. The efferent limbs
of the baroreflex loop consist of sympathetic and parasym-
pathetic fibres to the heart as well as to blood vessels.
E X P E R I M E N T A L  A N D  I A T R O G E N I C
D E N E R V A T I O N  O F  B A R O R E C E P T O R S
Arterial baroreceptors provide a tonic inhibitory influence
on sympathetic tone, thus controlling peripheral vasocon-
striction and cardiac output.1,2 Therefore, baroreceptor
denervation would be expected to result in a sustained
increase in sympathetic tone and, as a consequence, a
sustained increase in blood pressure. Indeed, experimental
denervation of carotid, aortic and cardiopulmonary
baroreceptors in dogs produces a persistent increase in
blood pressure level and variability.5 Following selective
carotid and/or aortic baroreceptor denervation, the increase
in blood pressure and heart rate is usually temporary.5-8
The first report on baroreceptor denervation in humans
appeared in the 1930s.9 Unilateral section of the glosso-
pharyngeal nerve in five patients with glossopharyngeal
neuralgia produced a prompt and pronounced rise in
blood pressure, which lasted 5 to 12 days. In 1956, a
patient died from a fatal hypertensive crisis following
unilateral carotid sinus denervation, which had been
performed for the relief of recurrent syncope due to a
M A Y  2 0 0 4 ,  V O L .  6 2 ,  N O .  5
© 2004 Van Zuiden Communications B.V. All rights reserved.
151
R E V I E W
Baroreflex failure: a neglected type of 
secondary hypertension
H.J.L.M. Timmers1*, W. Wieling2, J.M. Karemaker3, J.W.M. Lenders1
1Department of Internal Medicine, University Medical Centre St Radboud, PO Box 9101, 
6500 HB Nijmegen, the Netherlands, tel.: +31 (0)24-361 88 19, fax: +31 (0)24-354 17 34, 
e-mail: H.Timmers@aig.umcn.nl, Departments of 2Internal Medicine and 3Physiology, Academic
Medical Centre, PO Box 22660, 100 DD Amsterdam, the Netherlands, * corresponding author
hypersensitive carotid sinus syndrome.10 In 1985, Fagius
and Wallin reported the effects of experimental chemical
blockade of carotid baroreceptors in humans.11 These authors
performed bilateral anaesthetic blockade of vagal and glos-
sopharyngeal nerves upon each other, which resulted in an
elevation of blood pressure and tachycardia, accompanied
by a strong increase in muscle sympathetic nerve activity. 
Apart from these experimental studies, inadvertent baro-
receptor denervation may occur as a complication of bilateral
carotid body tumour resection,12-14 radiotherapy and surgery
for laryngeal/pharyngeal carcinoma,12,15,16 bilateral17,18 and
unilateral19,20 carotid endartectomy and trauma of the neck.12
Disruption of the baroreflex has also been reported in the
event of ischaemic or neurodegenerative lesion of the nucleus
tractus solitarii.21 The clinical syndrome of baroreflex failure
has now been characterised as a separate clinical entity.12,22
B A R O R E F L E X  F A I L U R E  S Y N D R O M E
The acute form of baroreflex failure is encountered follow-
ing loss of glossopharyngeal or carotid sinus nerve function
due to surgical intervention or accidental injury.17-20 It is
characterised by severe, unremitting hypertension, tachy-
cardia, and headache (table 1). The systolic blood pressure
typically exceeds 250 mmHg,22 which may lead to hyperten-
sive encephalopathy17,19 and (fatal) cerebral haemorrhage.10,20
Hypertensive crisis may evolve over days and weeks into
the more chronic volatile hypertension phase.12,14,18,23,24 In
addition, votatile hypertension may result from a gradual
decline in baroreflex function due to neck irradiation.12,16
Irradiation may affect the stretch-induced afferent baro-
receptor activity due to direct trauma of baroreceptors or
by inducing atherosclerosis and fibrosis of the carotid
sinus arterial wall.25-27 Volatile hypertension due to baro-
reflex failure is characterised by paroxysms of abrupt sympa-
thetic activation, including excessive increments in plasma
catecholamine levels.12,22 Surges of blood pressure and
tachycardia may occur spontaneously or are elicited by
mental stress or physical stimuli such as exercise, cold and
sexual arousal.28 These bouts of sympathetic activation
may be accompanied by severe headache, palpitations,
diaphoresis, light-headedness and anxiety.12 Intraocular
pressure may be increased.29 In addition, emotional
instability appears to be a prominent feature in this phase
of baroreflex failure. Apart from hypertensive surges,
hypotensive valleys may occur during sleep.16 In rare cases,
inadequate baroreflex buffering of cardiovagal efference
is the most prominent feature, resulting in malignant
vagotonia with hypotension, bradycardia, and asystole.30
Accompanying symptoms of this so-called ‘selective
baroreflex failure’ include fatigue and dizziness, with
possible progression to frank syncope.
W H E N  S H O U L D  B A R O R E F L E X  F A I L U R E
B E  C O N S I D E R E D ?
A history of prior (iatrogenic) trauma of the neck is the most
important clue in suspecting the diagnosis of baroreflex
failure. The diagnosis of baroreflex failure should be con-
sidered in patients with a negative work-up for pheochromo-
cytoma, since this carries a strong clinical resemblance to
baroreflex failure. Apart from pheochromocytoma, which
should be ruled out by the proper biochemical and radio-
graphic investigations, the differential diagnosis of baro-
reflex failure includes paroxysmal tachycardia, migraine,
hyperthyroidism, renovascular hypertension, alcohol
withdrawal, drug use (e.g. amphetamines or cocaine),
mastocytosis, carcinoid syndrome, intracranial lesions
and psychological disorders (panic attack, generalised
anxiety disorder).22
Labile hypertension and hypotension can be demonstrated
by a 24-hour ambulatory blood pressure recording.17 Patients
with a suspicion of baroreflex failure should be referred
Timmers, et al. Baroreflex failure.
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Table 1
Symptoms and signs of baroreflex failure
ACUTE PHASE FOLLOWING BARORECEPTOR DENERVATION 
(DAYS-WEEKS)
Severe sustained elevation of blood pressure (systolic pressure
typically >250 mmHg)
Tachycardia
Elevation of plasma catecholamines
Headache
Complications of hypertension Encephalopathy
Cerebral haemorrhage
CHRONIC PHASE (WEEKS-YEARS)
Common
Volatile hypertension and tachycardia
Paroxysm of Palpitations
Headache
Diaphoresis
Light headedness
Anxiety
Emotional instability
Increased intraocular pressure
Rare
Hypotension (during sleep)
Bradycardia, asystole
Fatigue
(Orthostatic) dizziness
Syncope
to a specialised centre for the evaluation of autonomic
cardiovascular function. Disruption of the baroreflex arch
is demonstrated by absence of reflex bradycardia and
tachycardia in response to intravenous injection of pressor
drugs such as phenylephrine and depressor drugs as nitro-
prusside, respectively.12,31 The baroreflex modulation of
muscle sympathetic nerve activity can be assessed by micro-
neurography of sympathetic fibres within the peroneal nerve
(figure 1).32,33 Additional cardiovascular reflex tests such as
Valsalva's manoeuvre, standing up, forced breathing, cold
face test, cold pressor test and mental arithmetic34 can be
used to tease out the localisation of the baroreflex lesion.34
Baroreflex failure is essentially different from autonomic
neuropathy, which is either primary (pure autonomic failure,
multiple system atrophy) or secondary (e.g. diabetes mel-
litus). In contrast to baroreflex failure which is caused by
lesions of the afferent innervation of baroreceptors, auto-
nomic neuropathy is characterised by abnormal efferent
innervation to the heart and resistance vessels. The key
feature of autonomic neuropathy is (severe) orthostatic
hypotension.35 Syncope due to the hypersensitive carotid
sinus syndrome is caused by excessive afferent nerve
impulses towards the brainstem, causing cardioinhibition
and/ or vasodepression resulting in syncope.36
T R E A T M E N T  A N D  P R O G N O S I S
Information on the treatment of acute, postsurgical
baroreflex failure is scarce and relies on observational case
studies. As in any form of hypertensive crisis, antihyper-
tensive treatment in baroreflex failure is aimed at the
prevention of hypertensive encephalopathy, (cerebral)
haemorrhage, myocardial infarction, heart failure and
hypertensive retinopathy. Haemodynamic monitoring
of these patients in a medium or intensive care unit is
warranted in the acute phase. Theoretically, intravenous
administration of drugs with a short half-life is preferred
in view of the strong blood pressure lability. Drugs that
have been used in this setting include nitroprusside,
phentolamine and labetalol.37,38 Apart from antihypertensive
treatment, adequate analgesic and sedative therapy for
relief of postsurgical discomfort and baroreflex failure
related symptoms such as headache and palpitations are
indicated.
In the phase of labile hypertension, the primary goal of
therapy is to reduce the frequency and magnitude of surges
in blood pressure and heart rate. Clonidine, a centrally
and peripherally acting -adrenoreceptor and imidazoline
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Figure 1
Assessment of baroreflex control of heart rate (upper panel) and muscle sympathetic nerve activity (lower panel) in a
normal subject. Nitroprusside-induced hypotension elicits a baroreflex mediated increase in heart rate and muscle
sympathetic nerve activity. BP = blood pressure, HR = heart rate.
agonist, has been shown to reduce both frequency and
severity of pressor surges.12,20-22 Both central inhibition of
noradrenergic neurotransmission and sedative effects
may contribute to the beneficial effect of clonidine in
baroreflex failure. If tolerated by the patient, daily doses
as high as 1.2 to 2.4 mg may be required. The -adreno-
receptor blocker phenoxybenzamine has also been shown
to reduce the magnitude of blood pressure surges.12 In
patients who have been well controlled for months to years,
clonidine may be tapered off and replaced by high doses
of benzodiazepines, such as diazepam.22 Apart from these
agents, experimental treatment of baroreflex failure includes
(non-registered) inhibitors of norepinephrine release. 
Agents that increase synaptic norepinephrine concentra-
tions and may thereby elicit profound pressor responses
are probably better avoided in baroreflex failure.22 These
include tricyclic antidepressants, amphetamines, mono
amino oxidase A inhibitors, cocaine, and tyramine-contain-
ing food and beverages. Additional nonpharmacological
strategies include avoidance of individual factors that
evoke sympathetic surges and (relaxation) biofeedback
training.39-41 In the rare patients with malignant vagotonia
due to selective baroreflex failure, insertion of a pacemaker
may be necessary.30 In the rare patients with predominant
hypotension, low doses of fludrocortisone and increased
dietary salt may be indicated.22 Regarding the polar shifts
in blood pressure, treatment of baroreflex failure can be
challenging and frequent follow-up of patients is warranted.
The clinical expression of baroreflex failure varies consid-
erably among patients, probably depending on the extent
of denervation of baroreceptors. In addition, the natural
cause of baroreflex failure is unpredictable. In most cases,
the pressor surges attenuate over time, but in some cases,
volatile hypertension is permanent.12
C O N C L U S I O N
Baroreceptors are essential for buffering acute changes in
blood pressure and prevent it from rising or declining
excessively. The syndrome of baroreflex failure results from
denervation of arterial and/or cardiopulmonary barorecep-
tors and is characterised by labile hypertension and rarely
hypotension. Baroreflex failure is particularly likely to
develop following carotid body tumour surgery, carotid
artery surgery, neck irradiation and injury. Baroreflex failure
should be considered in the differential diagnosis both of
the cases with (severe) hypertension with a striking blood
pressure variability and in patients with suspected
pheochromocytoma. Referral to a specialised centre for
correct diagnosis and specific therapy is warranted.
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A B S T R A C T
HFE-related hereditary haemochromatosis is the most
common autosomal recessive disorder in the Caucasian
population. In 1996 the responsible gene (called HFE)
was identified. Two mutations (C282Y and H63D) are
considered most important and occur frequently in the
Caucasian population.
We describe a family of an affected proband in which first-
and second-degree relatives were tested phenotypically and
genotypically. In second-degree relatives both C282Y homo-
zygosity as well as compound heterozygosity were found.
Family testing can be useful to detect persons who will
possibly develop iron overload. We must be aware that
testing first-degree relatives only carries a 2.5% chance
that persons at risk of developing iron loading will not be
detected. Cascade screening of second-degree relatives
might be cost-effective.
I N T R O D U C T I O N
HFE-related hereditary haemochromatosis (HFErHH) is
the most common autosomal recessive disorder in the
Caucasian population,1 the prevalence ranging from 0.25
to 0.5%.2-4 A common trait of the disease is iron loading in
tissues and organs such as liver, heart, joints, pancreas and
pituitary gland. Ultimately this can lead to liver cirrhosis,
cardiomyopathy, arthropathy, diabetes mellitus and
hypogonadism.
In 1996 the gene responsible for HFE-related hereditary
haemochromatosis (called HFE gene, coding for the HFE
protein) was identified.5 The HFE protein is involved in
the regulation of iron absorption.6 Multiple mutations in
the HFE gene have been described.7 The most important
one is the C282Y mutation, which means that at amino-acid
282 cysteine is substituted by tyrosine. A second (H63D,
aspartate-to-histidine substitution at amino-acid 63) is also
considered of importance.
The C282Y and H63D mutations occur frequently in the
Caucasian population (see table 1).8 Among all Caucasian
HFErHH patients 80 to 90% are homozygous for the
C282Y mutation, 1% is homozygous for the H63D mutation,
5% are compound heterozygous (which means heterozygous
for both the C282Y as well as the H63D mutation), and 
3 to 10% are heterozygous for either C282Y or H63D
mutation, possibly with other mutations.9
Since the discovery of the HFE gene, it is possible to detect
persons at risk of developing haemochromatosis in a
presymptomatic stage. The Dutch Haemochromatosis
Association advises testing of first-degree relatives of
affected probands.10 In this original article, we will
describe a family in which C282Y homozygosity and
compound heterozygosity were found in second-degree
relatives. The role and extent of genetic testing of families
of affected probands will be discussed.
C A S E  R E P O R T
Patient A, 60 years old and diagnosed with diabetes
mellitus nine years ago, presented with complaints of
chronic fatigue. Physical examination did not reveal any
abnormalities. Blood examination had the following
results (reference range between brackets): haemoglobin
10.3 mmol/l (8.5-10.9), mean corpuscular volume 94 fl
(80-100), aspartate aminotransferase 76 U/l (<40), alanine
© 2004 Van Zuiden Communications B.V. All rights reserved.
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aminotransferase 79 U/l (<45), lactic dehydrogenase
976 U/l (<450), -glutamyl transpeptidase 216 U/l (<50),
alkaline phosphatase 154 U/l (40-120), ferritin 1318 g/l
(30-300), iron 39 g/l (14-28), iron-binding capacity 55 g/l
(45-77) and transferrin saturation (iron divided by iron-
binding capacity) 71% (<45%). Ultrasound examination of
the liver showed no abnormalities. Serological testing for
infection with hepatitis A, B and C, Epstein-Barr virus and
cytomegaly virus was negative. Liver biopsy showed iron
loading with mild periportal fibrosis. The patient turned
out to be C282Y homozygous.
Testing of family members
All first- and second-degree relatives of the patient were
tested both phenotypically (ferritin and transferrin satura-
tion) and genotypically. The spouses of some of the first-
degree relatives were tested as well. The results of this
screening are shown in the family tree (figure 1) and table 2.
Among the ten first-degree relatives one C282Y homozygote
was found. Among ten second-degree relatives two com-
pound heterozygotes and one C282Y homozygote were
found.
D I S C U S S I O N
HFE-related hereditary haemochromatosis seems to be a
favourable disorder for screening. The disease has a long
presymptomatic phase, an economical and simple treat-
ment is available and – if treated in time – patients have
the same life-expectancy as healthy persons.11
Two modalities exist for screening haemochromatosis:
phenotypic testing (ferritin level and transferrin saturation)
and genotypic testing (DNA examination). 
Phenotypic testing detects persons with elevated iron stores.
However, phenotypic testing is a one-time measurement,
so a normal test result does not exclude future iron loading.
Genotypic testing detects persons who are at risk of
developing iron overload, but not all detected persons will
develop iron loading, indicating that HFE-related hereditary
haemochromatosis is not a monogenetic disorder.
Therefore, genotypic population screening for HFE-related
hereditary haemochromatosis is still a matter of debate,
because the clinical penetrance of the disorder (that means
the percentage of persons with an ‘at risk’ genotype who
will develop symptomatic iron loading) seems to be much
lower than previously thought. Although C282Y homozy-
gosity has a phenotypic expression (elevated ferritin and
transferrin saturation) of 50 to 90%,12,13 the importance
with respect to morbidity and mortality seems to be low.
Beutler et al. found 152 C282Y homozygotes in a group of
41,038 healthy volunteers.13 Complaints and symptoms
that could be ascribed to haemochromatosis were not more
prevalent in these C282Y homozygotes than in a control
group, so that the clinical penetrance in this study was
only 1%. 
In contrast to population screening, family testing is an
accepted screening strategy to detect asymptomatic persons
with (an elevated risk for) iron loading. Detecting a C282Y
homozygote with elevated iron stores implies phlebotomy
therapy, whereas C282Y homozygotes without phenotypic
expression should be re-tested phenotypically within several
years. In contrast to C282Y homozygosity, the relevance
of compound heterozygosity appears to be much lower
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Table 1
Distribution of genotype in the Caucasian population and in HH patients
CAUCASIAN POPULATION HFE-RELATED HEREDITARY 
HAEMOCHROMATOSIS PATIENTS
C282Y/C282Y (homozygosity) 0.5% 80-90%
H63D/H63D (homozygosity) 2% 1%
C282Y/H63D (compound heterozygosity) 2% 5%
C282Y/WT (heterozygosity) 10% Rest
H63D/WT (heterozygosity) 20% Rest
WT = wildtype = unmutated gene.
Figure 1
since only 1 to 2% with this genotype develop a mild iron
loading.14 As can be seen from figure 1 and table 2, genotype
and phenotype often correlate poorly. However, the C282Y
homozygote in the second-degree relatives (no. 20) was
still young and it is possible that she will develop iron
loading later in life. Furthermore, elevated iron parameters
can be caused by conditions other than HFE-related
hereditary haemochromatosis, as was recently discussed
by Jacobs et al.15
The Dutch Haemochromatosis Association advises testing
of first-degree relatives (siblings, children, parents) of C282Y
homozygous patients both phenotypically and genotypically.
In our patient second-degree relatives were tested as well.
Among these second-degree relatives both C282Y homo-
zygosity and compound heterozygosity were found, which
means that spouses of first-degree relatives had introduced
a C282Y and a H63D mutation into the family. 
As is the case in the general population, relatives of patients
with HFE-related hereditary haemochromatosis with an
‘at risk’ genotype do not inevitably develop iron loading.
However, in families the clinical penetrance of C282Y,
homozygosity appears to be higher than in the general
population and is reported to be 40 to 67%.16 Bulaj et al.
examined the penetrance in 214 C282Y homozygotes,
including second-degree relatives, who were detected by
family testing.17 From all men, 85% had an increased iron
supply, 38% had signs and/or symptoms that could be
ascribed to iron loading, including liver cirrhosis in 12%.
However, a control group was not included in this study. 
Because of this higher clinical penetrance it can be ques-
tioned whether family testing for HFE-related hereditary
haemochromatosis should include second-degree relatives.
Extended family testing (first to third degree) has been
advocated as an alternative to population screening, leading
to detection of 40% of C282Y homozygotes.18 It is thought
that the higher penetrance in families is caused by additional
genetic and environmental factors that promote penetrance,
although a search for such genetic factors was unreward-
ing.19 In second-degree relatives a dilution of these pene-
trance-promoting factors is expected. However, the magnitude
and effect of this expected dilution is unknown so the
penetrance in second-degree relatives is difficult to predict.
A current two-year multicentre study of the clinical pene-
trance in first-degree relatives of Dutch HFE-related
hereditary haemochromatosis patients will hopefully shed
some light on this issue (www.zonmw.nl). If penetrance
in these first-degree relatives turns out to be low, screening
second-degree relatives will probably not be cost-effective.
However, if the penetrance is in the reported range of 50%,
a study of penetrance in second-degree relatives is needed.
The chance of C282Y homozygosity in second-degree
relatives of a C282Y homozygous index patient can be
calculated as follows:
0.5 (= the chance of having a heterozygous sibling) x 0.1
(= the chance of a heterozygous spouse) x 0.25 (= the
chance that both parents pass the mutation to their off-
spring) = 1.25%
+
0.25 (= the chance of having a homozygous sibling) x 0.1
(= the chance of a heterozygous spouse) x 0.5 (= the chance
that the spouse passes the mutation) = 1.25%
Total = 2.5%*
*In this calculation C282Y heterozygosity of the parents
of the index patient is assumed and the chance of a
homozygous spouse is neglected.
At first sight this chance seems rather small. However,
the yield of genetic testing in second-degree relatives can
be enhanced by first testing the spouse of the first-degree
relative (so-called cascade screening). If the sibling is C282Y
heterozygous or homozygous, the spouse should be tested.
The initial increase in costs and number of persons that
need to be tested will be 75%. If the spouse carries no
mutation, testing the children can be omitted. However, if
the spouse is C282Y heterozygous (10% chance) there is
at least a 25% chance of C282Y homozygosity in their off-
spring, which is the same as for siblings of the proband.
The above-described approach proved to be cost-effective in
screening children of affected probands.20 The difference
in chance of C282Y homozygosity between children (5%)
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Table 2
Phenotype of the tested family members
Family member 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Iron 39 5 * 17 18 15 8 19 5 28 15 23 37 14 22 26 24 63 4 11 16 12 22
TIBC 55 52 * 63 75 72 77 89 74 67 70 98 68 87 67 84 76 88 115 57 83 76 74
Tf-saturation 71 10 * 27 24 20 11 21 7 41 21 23 54 16 33 31 31 71 4 19 19 16 30
Ferritin 1318 355 580 40 42 37 159 77 10 109 397 44 182 37 91 148 54 42 122 213 41 145 242
Age 60 57 55 54 53 49 46 44 36 34 31 29 26 30 27 24 22 18 21 18 13 52 49
TIBC = total iron-binding capacity, Tf = transferritin, * not available.
and second-degree relatives (2.5%) is rather small.
However, in the aforementioned study the clinical pene-
trance in children was assumed to be 40%, whereas the
penetrance in second-degree relatives is unknown. The
findings of this study cannot thus be automatically extra-
polated to screening second-degree relatives.
It has been argued that detecting asymptomatic C282Y
homozygotes would impose a psychological and economical
burden upon these persons. Insurance denial has indeed
been reported. However, a recent study showed that the
quality of life and psychological well-being in asymptomatic
C282Y homozygotes detected by screening is not different
from unaffected persons.
In conclusion, testing second-degree relatives of patients
with HFE-related haemochromatosis can be helpful in
detecting persons who will possibly develop iron loading
in the future. Testing first-degree relatives only implies a
2.5% chance that persons who are at risk for developing
iron loading will not be detected. Testing second-degree
relatives by means of cascade screening might be cost-
effective. However, before recommendations on screening
second-degree relatives can be made, studies to cost-effective-
ness and penetrance are needed. 
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A B S T R A C T
Background: We recently described a new autosomal
recessive type of Ehlers-Danlos syndrome (EDS) based on
a deficiency of the extracellular matrix protein tenascin-X
(TNX). TNX-deficient patients have hypermobile joints,
hyperextensible skin and show easy bruising. Because of the
reported cardiovascular abnormalities in other EDS types
and the excessive haematoma formation after mild trauma
in TNX-deficient individuals, we investigated whether cardio-
vascular or coagulation abnormalities occur in these patients. 
Methods: We examined seven TNX-deficient patients. One
of them had a mitral valve prolapse and died postoperatively
after valve replacement, before the study was completed. 
Results: Bleeding time and coagulation factors (INR, APTT,
PT and fibrinogen) were all within the normal range. Ultra-
sonographic examination of the carotid and femoral arteries
showed normal vessel wall compliance and distensibility.
Echocardiography showed a slight billowing of the mitral
valve in two patients from one family. All patients had
normal diameters of aortic root and ascending aorta. 
Conclusion: Although the patient group is small, there are
no indications of generalised cardiovascular abnormalities
in this type of EDS. We would recommend echocardiography
for all these patients at the first evaluation and when a
cardiac murmur appears.
I N T R O D U C T I O N
Ehlers-Danlos syndrome (EDS) is a heterogeneous group
of inherited connective tissue disorders characterised by
hyperextensibility of the skin, hypermobility of joints and
tissue fragility which results in easy bruising and (in the
classical type) atrophic scars following superficial injury.
Six well-defined types of EDS have been described1 and
the syndrome is generally regarded as a disorder of fibrillar
collagen. Recently, we showed that deficiency of the extra-
cellular matrix protein tenascin-X (TNX), encoded by the
TNXB gene, causes a new type of EDS with autosomal
recessive inheritance.2 Patients with a complete deficiency
of TNX showed marked joint hypermobility, skin hyper-
extensibility and easy bruising, resembling the classical
type of EDS. The six patients studied showed a variety of
other clinical manifestations (such as spina bifida occulta,
IgA deficiency, gastrointestinal bleeding, arteriosclerosis,
goiter) although it is not clear whether these are causally
related to TNX deficiency.
TNX deficiency is associated with abnormalities in collagen
and elastic fibres,3,4 which are principal components of heart
valves and large vessels. Cardiac abnormalities such as mitral
valve prolapse and aortic dilatation are reported to be
common features of certain EDS types,1,5 although this has
been questioned in a more recent paper.6 Here we under-
took an echocardiographic examination of six patients who
were available for study and we investigated vessel wall
properties of carotid and femoral arteries by ultrasonography. 
All these patients had excessive haematomas after relatively
mild trauma or spontaneous haematomas. Although the
most likely explanation for this phenomenon is vascular
fragility due to connective tissue abnormalities, we wanted to
exclude the possibility that the absence of serum TNX
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caused abnormalities in coagulation. We therefore tested
platelet function and performed screening coagulation tests. 
M A T E R I A L S  A N D  M E T H O D S
Patients
Six TNX-deficient patients were seen in our outpatient clinic.
Three of them were identified through analysis of serum
TNX levels in 151 Ehlers-Danlos patients. The other three
were siblings. Initially we included seven patients; one of
these patients died following cardiac surgery because of
sepsis after a mitral valve replacement. These patients
were described earlier.2
Clinical features
From the six patients medical history was recorded and
physical examination was carried out with an emphasis
on joint hypermobility, which was scored on a nine-point
scale according to Beighton.1 An electrocardiogram was
performed in all patients.
Laboratory measurements
Blood was taken for measurement of screening coagulation
tests (INR, APTT, PT and fibrinogen). Platelet function
was tested by means of Ivy, simplate and aggregation
tests. Von Willebrand factor was measured as a marker
for endothelial function
Echocardiography 
All patients underwent echocardiography, which was per-
formed with standard equipment (GE ultrasound systems,
Vingmed V, Horten, Norway, with second harmonic imaging
(octave mode: transmit frequency of 1.7-1.9 MHz, receive
frequency of 3.4-3.8 MHz)). Digitised measurements of the
aortic root were taken in two-dimensional parasternal long-axis
views at end diastole using the leading-edge technique at the
four aortic levels described by Roman et al.:7 at the annulus,
sinuses of Valsalva, supra-aortic ridge and proximal ascending
aorta. Echocardiographic evidence of mitral valve prolapse
consisted of severe bowing of the anterior and/or posterior
mitral valve leaflet(s) into the left atrium and with the coapta-
tion point of the leaflets on the atrial side of the mitral annu-
lus.8 If the mitral valve leaflets showed bowing but the coapta-
tion point was still on the ventricular side of the annulus
or at the level of the annulus it was defined as ‘billowing’.
Vessel wall compliance
Cross-sectional compliance (CC) and distensibility coeffi-
cients (DC) are defined as the absolute and relative change
in volume for a given change in pressure, respectively. Since
arterial volume cannot be measured directly, simplified
models have been used which assume that arteries have a
circular shape and that the arterial length does not change
during the cardiac cycle. With this simplification, CC and DC
of separate arteries can be assessed by measuring diameters
and diameter changes ultrasonographically using a vessel
wall movement detector (Wall Track System, Maastricht,
the Netherlands) as described by the group of Hoeks and
Reneman.9,10 Measurements were performed by one person
according to a protocol described by Van den Berkmortel
et al.11 Traces were recorded at the following sites: 1) the right
and left common carotid arteries (2 cm proximal of the bulb);
2) the right common femoral artery (at least 1 cm proximal of
the bifurcation into the deep and superficial femoral artery).
R E S U L T S
All TNX-deficient patients had hyperextensible skin, hyper-
mobile joints and easy bruising, as reported earlier. There
were no signs of atrophic scarring. One of the patients had
coexisting congenital adrenal hyperplasia. Three patients
complained of recurrent (sub)luxation/dislocation of joints
and two patients had chronic joint pain. 
One patient had a mild systolic murmur at the apex; the
other patients had normal heart sounds. The electrocardio-
gram showed no abnormalities. Echocardiographic analysis
showed no evident mitral valve prolapse, but two patients
of the same family had billowing of the mitral valve. The
diameter of the ascending aorta and aortic root was normal
in all six patients available for study. Initially we included
seven patients in this study. This seventh patient had a mitral
valve prolapse that was complicated by a Staphylococcus
aureus endocarditis in 1990. Mitral valve replacement was
performed in July 2002. During surgery, the tissues of the
patient appeared fragile and bled easily. Unfortunately, the
patient died 16 days postoperatively due to sepsis. The mitral
valve showed excessive tissue and a chorda rupture of the
anterior mitral valve leaflet; microscopically there were
myxoid degenerative changes. We did not observe fragmen-
tation and clumping of elastic fibres in this mitral valve as we
recently found for the dermal elastic fibres in these patients.4
There were no signs of neovascularisation or inflammation. 
As large arteries are also rich in elastic fibres we examined
the vessel wall compliance and distensibility of these arteries;
these results were comparable with those of earlier measure-
ments from healthy controls.12 Screening coagulation tests
and platelet function tests were also normal.
D I S C U S S I O N
There are several reports showing a high prevalence of
cardiovascular abnormalities in EDS patients. Aortic
rupture as seen in the vascular type of EDS is the most
serious complication but also in the classical type of EDS
cardiovascular complications were observed (Leier et al.)5 In
Peeters, et al. Ehlers-Danlos syndrome patients with complete deficiency of tenascin-x.
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hypermobility syndrome patients, Grahame et al. found
mitral valve prolapse to be more frequent in patients with
a high hypermobility score, but echocardiography was only
performed with the M-mode technique.13 A more recent
study by Dolan et al. showed no evidence of increased
frequency of mitral valve prolapse in patients with EDS.6
This apparent discrepancy can be explained by a possible
bias in the study by Leier et al. because a substantial number
of the reported patients in that study initially presented to
a cardiologist.5 In our study, two patients of the same family
had billowing of the mitral valve and one unrelated patient
had a mitral valve prolapse. Because of the small patient
group it is too preliminary to conclude that there is an asso-
ciation between TNX-deficient type EDS and cardiac abnor-
malities. In addition, billowing and prolapse of the mitral
valve are not uncommon in the general population. Studies
show a prevalence of 1 to 2%.14,15
At this point, no general recommendation can be made as
to whether all EDS patients should be subjected to echocar-
diography. Former studies show that cardiac abnormalities
and aortic root dilatation occur in all subtypes of EDS5,16,17
but studies on the prevalence of cardiac abnormalities
within the specific EDS subtypes and studies concerning
long-term outcome of the cardiovascular abnormalities
have not been carried out. The EDS type based on TNX
deficiency described here can easily be discriminated from
the other types, because of the absence of atrophic scarring
and family history. We would recommend echocardiography
for these patients at the first evaluation and when a cardiac
murmur appears. If there is a mitral valve prolapse with
coexisting mitral insufficiency patients should be followed
yearly or every other year according to the severity of the
disorder. In case of interventions patients should be treated
according to the endocarditis prophylaxis.
We recently found that dermal elastic fibre structure is
disturbed in TNX-deficient patients.3,4 Whether these
patients suffer from a more generalised elastinopathy
remains to be investigated. Our measurements of arterial
vessel wall mechanical properties showed no evident
abnormalities nor did we observe abnormal elastic fibres in
the mitral valve that was available for study. In large blood
vessels there is co-expression of TNX and tenascin-C (TNC),
which is another member of the tenascin gene family.18
TNC could possibly compensate for the absence of TNX
leading to normal vessel wall properties.
One of the clinical features of the TNX-deficient patients 
is easy bruising. This could be caused by mechanical fragility
of the vascular connective tissue. Since a 140 kDa TNX frag-
ment is present in plasma, this could theoretically affect the
intrinsic coagulation properties. We found, however, no
impaired coagulation in these patients. 
In conclusion, we would recommend echocardiography
for patients with EDS due to TNX deficiency, at the first
evaluation and when a cardiac murmur appears.
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P H O T O  Q U I Z
A 72-year-old patient with diarrhoea and
abdominal pain
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C A S E  R E P O R T
A 72-year-old diabetic male was referred by his general practitioner because of gradually increasing diarrhoea and abdominal
pain over several days. On examination, he had mild acidotic breathing, and he appeared slightly dehydrated. The abdomen
was distended and tender on palpation. Blood chemistry revealed slight derangement of his diabetes, and a neutrophil
count of 12 x 109/l, liver enzymes were slightly elevated (ASAT 60, ALAT 70 U/l). During clinical observation, symptoms
worsened, and a plain abdominal radiograph was performed (figure 1). 
W H A T  I S  Y O U R  D I A G N O S I S ?
See page 175 for the answer to this photo quiz.
Figure 1
Plain abdominal (antero-posterior) radiograph in supine position
A B S T R A C T
A 63-year-old woman presented to the internist with fatigue,
cough, low-grade fever, splenomegaly and leucocytosis up
to 130 x 109/l. Although a diagnosis of chronic myelogenous
leukaemia was initially entertained, she turned out to have
a metastasised melanoma.
The differential diagnosis and workup is discussed, as well
as potential mechanisms by which the tumour could have
induced the leucocytosis, such as the production of G-CSF
or similar mediators, and the prognostic significance of
this phenomenon.
C A S E  R E P O R T
A 63-year-old woman was referred to the internist because
of progressive fatigue and breathlessness for several months.
She even got breathless from talking. She had lost 15 kg
of weight and had intermittent fevers up to 38.6°C. There
were no night sweats. Several courses of oral broad-spec-
trum antibiotics had not had any effect on her symptoms.
The previous medical history was unremarkable apart from
an unspecified lung operation at the age of 13 and chronic
obstructive pulmonary disease. Ten months earlier a
melanoma had been removed from her left ankle, histo-
logically Breslow depth 1.5 mm and Clarke level III. Her
medication consisted of inhaled bronchodilatators, steroids
and acetylcysteine. The family history included a brother
with multiple sclerosis and a brother with colonic carcinoma.
On physical examination a pale and breathless woman was
seen. She was 1.65 m tall and her weight was 60.3 kg.
The pulse was 100 beats/min, blood pressure 120/70
mmHg and rectal temperature 39.0°C. There were no
enlarged lymph nodes and no pathological findings of
heart and lungs. No breast lumps were palpable. Her
liver was palpable under the right costal margin and the
spleen was palpable 10 cm under the left costal margin.
There was no peripheral oedema and no other findings at
the extremities.
Laboratory findings were: Hb 5.5 mmol/l (8.91 mg/dl),
thrombocyte count 377 x 109/l, leucocyte count 62.4 x 109/l
(differential: neutrophils 73%, eosinophils 11%, basophils
0%, lymphocytes 11%, monocytes 4%, some metamyelo-
cytes and myelocytes; erythroblasts were not observed).
The electrolytes and renal function were normal.
Liverfunction tests: ASAT 21 U/l, ALAT 12 U/l, LDH 527
U/l, alkaline phosphatase 295 U/l, GT 196 U/l, ferritin
379 g/l and serum iron 3.1 mol/CRP was elevated at
101 mg/l.
Bone marrow biopsy showed hypercellular bone marrow
with all cell lines represented, though a strong increase in
granulopoeisis was seen. Occasionally some very atypical
cells were seen with polymorphic hyperchromatic nuclei,
a coarse chromatin pattern and enlarged nucleoli.
Bone marrow cytology showed an increased granulopoeisis
(70%) with moderate left shift, 2% blasts, increase of
eosinophilic elements (14%) with multiple precursors.
There was decreased erythropoiesis and megakaryopoiesis.
Scattered through the marrow there were large, very atypical
cells with an epitheloid aspect, one or more round to oval
nuclei, abundant cytoplasm which sporadically contained
blue-grey granula (see figure 1). These cells were identified
as (amelanotic) melanoma cells.
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C A S E  R E P O R T
Extreme leucocytosis and splenomegaly in
metastasised melanoma
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Cytogenetics showed 20 cells with a normal female
karyotype and no bcr-abl fusion on fluorescent in situ
hybridisation (FISH) in ten metaphases.
Blood cultures (two separate 3-10 ml aliquots containing
aerobic and anaerobic media) were negative. Mid-stream
urine examination showed several leucocytes per high-
power field and upon culture contained mixed bacterial
flora. Sputum was negative for auramine and Ziehl-
Neelsen staining but on culture showed Haemophilus
parainfluenzae.
Ultrasound examination of the abdomen showed an
enlarged liver with multiple lucencies, a very large spleen
of 20 cm with one lucency possibly due to metastasis,
some ascites and no enlarged lymph nodes.
Computed tomography (CT) of chest and abdomen showed
no signs of a primary tumour, signs of infiltration in the
left lower pulmonary lobe, many metastases in the liver
and a solitary one in the spleen, one pathological lymph
node around the abdominal aorta and some ascites.
Ultrasound-guided biopsy of one of the liver lesions
showed disseminated melanoma cells in small clusters and
marked granulocytosis of the sinusoids. Immunohisto-
chemical staining was positive for melanoma (HMB-45,
S100, Schmorl’s stain weak).
During the stay in hospital the leucocytosis increased to
130.3 x 109/l despite antibiotic therapy and the patient’s
condition worsened with night sweats and progressive
fatigue. She declined chemotherapy, and was released with
terminal home care; she died at home one day after dis-
charge. A postmortem examination was not performed.
D I S C U S S I O N
Extreme leucocytosis can be caused by infection, malig-
nancy and several other, less common causes. When
leucocyte counts exceed 50 x 109/l it is referred to as
‘leukaemoid reaction’ (see table 1). Reding et al. studied
100 patients presenting with leucocytosis exceeding 25 x
109/l and found infection as a cause in only 48%.1 In 15%
malignancy was diagnosed and in the remaining 37%
other, less common secondary causes were found (such
as haemorrhage, glucocorticoid therapy, rhG-CSF therapy).
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Table 1
Causes of neutrophilic leukaemoid reaction 
(leucocyte count >50 x 109/l)1,15
INFECTIONS
Pneumonia
Meningitis
Diphtheria
Tuberculosis
Shigellosis
INTOXICATIONS/MEDICATION
Mercury poisoning
Steroids
Adrenergic agents
All-trans retinoic acid (ATRA)
G-CSF
PHYSICAL CAUSES
Serious burns
MALIGNANCY
Bone metastasis
Multiple myeloma
Myelofibrosis
Hodgkin’s disease
Other malignancy
SERIOUS HAEMORRHAGE
ACUTE HAEMOLYSIS
ECLAMPSIA
PREMATURITY/NEONATES
HEREDITARY/CONGENITAL
Figure 1
Microscopy
Top: Bone marrow aspirate with large, very atypical cells
with an epitheloid aspect, one or more round to oval
nuclei (A), abundant cytoplasm containing sporadic
blue-grey granula (B).
Bottom: Liver biopsy (HMB-45 and S100 staining) with
agglomerates (C) of melanoma cells and marked hyper-
granulocytosis of the sinuses.
A
B
C
The leucocyte count was not predictive of the cause. The
15 patients with malignancy mostly had primary haemato-
logical disorders, but metastatic carcinoma was diagnosed
in six of them.
Fatigue, splenomegaly and leucocytosis as presenting
signs in a middle-aged patient all point at the possibility
of myeloproliferative syndrome (MPS). However, careful
review of the history, physical examination, infectious
parameters (such as blood culture, chest X-ray and mid-
stream urine specimen), blood film and bone marrow
aspirate and trephine can give clues as to a secondary
cause.
After excluding infectious disease and drug-related causes
of leucocytosis, the diagnostic effort should concentrate
on the possibility of malignancy. To differentiate between
primary haematological and secondary causes, normal to
low basophil granulocytes on the blood film, as well as
negative cytogenetics (no t(9;22)(q34;q11) translocation
causing bcr-abl fusion) make myeloproliferative disease
very unlikely.
There are roughly two ways in which nonhaematological
malignant disease can lead to leucocytosis. Firstly, bone
marrow invasion by metastases can cause a leucoerythro-
blastic picture. Secondly, an oft-reported form of leuco-
cytosis in malignancy is a leukaemoid reaction due to
production of cytokines or other mediators by tumour cells.
In our patient, infectious causes were considered unlikely,
with blood cultures remaining sterile all through the
patient’s stay in hospital. She was not taking any oral
medication associated with a raised leucocyte blood count.
The absence of bcr-abl fusion on cytogenetics and the
normal basophil count made the diagnosis of chronic
myelogenous leukaemia (CML) very unlikely (<5% of CML
patients are bcr-abl negative).2
The finding of metastatic lesions of the primary melanoma
in the liver biopsy, as well as malignant cells in the bone
marrow, confirmed the suspected diagnosis of tumour-
induced leucocytosis. Bone marrow infiltration as such
was not perceived to be an explanation for the symptoms,
given the absence of leucoerythroblastosis in the blood.
Therefore, the diagnosis was leukaemoid reaction due to
the production of a humoral factor by a primary
melanoma.
Virtually every type of malignant tumour has been reported
to induce leucocytosis, for example glioblastoma multi-
forme,3 head and neck carcinoma4 and malignant meso-
thelioma.5 Generally the secretion of G-CSF or GM-CSF,
most commonly the former,6 by the tumour cells seems
to be the predominant mechanism of the leukaemoid
reaction in malignancy.7
Malignant melanoma has been reported to secrete G-CSF
or GM-CSF,8-11 and this feature appears to be a marker of
poor prognosis.10 In the patient reported by Carey and Kunz11
the leucocytosis resolved when the adrenal metastases were
removed through bilateral adrenalectomy. Eosinophilic
leukaemoid reaction has been reported in a case of
melanoma secreting extremely high quantities of IL-5.12
Concerning the contribution of G-CSF production to a
tumour’s malignant potential, Safarians et al. found that
G-CSF-secreting melanoma cells do not express G-CSFR,
thereby ruling out an autocrine mechanism.10
Otherwise, G-CSF can stimulate endothelial proliferation
and migration, thereby assuring the tumour of a steady
blood supply through angiogenesis.13 Moreover, the
granulocytes themselves can benefit the tumour by in-
ducing further malignant transformation.14
Finally, Safarians et al. suggest that the expression of G-CSF
could be a side effect of the activation of other oncogenes,
which increase the tumour’s capability of malignant
transformation, growth and dissemination.10
C O N C L U S I O N
The diagnosis in this patient turned out to be metastasised
melanoma with extreme granulocytosis, possibly due to
G-CSF production by the tumour cells.
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Bijsluiter A
A B S T R A C T
We describe a 61-year-old patient who had been suffering
from chronic ulcers of both legs for 18 months. Initially,
his condition was diagnosed as ischaemic because of an
ankle-brachial index of 0.6, as confirmed by additional
angiography. 
A successful femoro-infragenual bypass procedure was
performed, but the ulcers increased in size and number.
He was then extensively analysed for a possible
(macro)vascular origin of his symptoms. Angiographic
analysis of both legs showed no arterial stenosis or occlu-
sion. Despite the extensive experience of the vascular sur-
geons with leg ulcers, consultations by internal medicine,
vascular medicine and dermatology, and tissue exami-
nation by our pathologists, pyoderma gangrenosum was
not recognised. During a multidisciplinary meeting one
of the specialists, to whom the lesions were shown,
immediately considered the diagnosis on clinical grounds.
The additional finding of IgG- paraproteinaemia and
improvement of the ulcers on treatment with cortico-
steroids were consistent with the diagnosis. Although the
majority of patients on the vascular surgery ward have
ulcers caused by ischaemia or a combined arterial/venous
origin, another (rare) cause, namely pyoderma gangre-
nosum in association with IgG- paraproteinaemia with-
out the presence of multiple myeloma, should be taken
into account. 
I N T R O D U C T I O N
Pyoderma gangrenosum (PG) is an uncommon, idiopathic,
chronic ulcerative inflammatory skin disease.1-5 Four types
of PG have been recognised: the ulcerative, pustular, bullous
and vegetative types.4 The first type is characterised by a
severely painful ulceration surrounded by an erythematous
halo. In the majority of the affected patients there is an
underlying condition, usually inflammatory bowel diseases
(such as ulcerative colitis, Crohn’s disease and diverticular
disease), arthritis (such as rheumatoid arthritis, spondyl-
arthropathy), chronic hepatitis and haematological malig-
nancy (including acute and chronic myeloid leukaemia,
myelofibrosis, lymphoma) and solid tumours of the colon,
bladder, prostate, breast, bronchus, ovary, and adrenocortical
carcinoma. This type is commonly located on the lower
limb, but location on the trunk, penis, head and neck,
breast, and ocular sites have also been reported. The ulcer-
ative form of PG typically affects people in the age range
25 to 55 years. The second type is also painful with pustules
again surrounded by an erythematous halo. This condition
is usually associated with inflammatory bowel disease
(ulcerative colitis) and rarely with polycythaemia rubra vera,
hepatobiliary disease and pyostomatitis vegetans. The third
type (also designated as atypical PG) is characterised by
painful vesicles, with a tendency to enlarge rapidly in
waves with central necrosis and erosion with an erythema
as a surrounding halo. This type is usually present in
© 2004 Van Zuiden Communications B.V. All rights reserved.
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C A S E  R E P O R T
Symmetrical, painful ulceration of the lower
limbs in a vascular surgery ward: a diagnostic
challenge 
Pyoderma gangrenosum associated with 
IgG- paraproteinaemia
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combination with haematological dyscrasias. Confusion
with Sweet’s disease (acute febrile neutrophilic dermatosis)
can easily occur. Sweet’s disease is very uncommon and
characterised by uncomfortable chronic erythematous
plaques with sinus discharge. Other disorders associated
with PG include HIV, hepatitis C, thyroid disease, diabetes
mellitus, cryoglobulinaemia, lupus erythematosus, der-
matomyositis, sarcoidosis, vasculitis (Wegener’s granulo-
matosis, Takayashu’s arteritis, Behçet’s disease) and parox-
ysmal nocturnal haemoglobinuria (table 1).
The association of the ulcerative type of PG with benign
monoclonal gammopathy, especially of immunoglobulin
A (IgA), has also been described.6-9 We report a patient
suffering from the ulcerative type of PG of both legs, which
was found to be associated with IgG- paraproteinaemia.
C A S E  R E P O R T
A 61-year-old patient was admitted to the department of
vascular surgery because of chronic ulcers of both legs
(for 18 months). These ulcers were initially identified as
ischaemic lesions (an ankle-brachial index of 0.6) and
femoro-infragenual bypass surgery was performed. Soon
after this operation, he developed more painful ulcers,
despite normalisation of the ankle-brachial index. Moreover,
subsequent angiographic analysis of the arteries of the legs
showed an open bypass without any indication for
(macro)vascular stenosis/occlusion. Duplex examination
did not show venous occlusion either. The patient had been
treated with several antibiotics, without any improvement
in the clinical situation. Then he was send to our university
hospital. Cardiovascular risk factors, including hypertension
and dyslipidaemia, were adequately controlled. He was
not complaining of headache, fever or changes in bowel
movement. Further medical history was unremarkable.
Physical examination revealed a normal blood pressure,
normal temperature, lack of tenderness of the temporal
arteries, and large ulcerations involving the pretibial area
of both legs, with blood and pus in the centre and a region
of deep necrosis (figure 1A). Laboratory data disclosed an
elevated erythrocyte sedimentation rate (100 mm/h), Hb
6.2 mmol/l, MCV 82 fl, leucocytosis 11.9 x 109/l with
90% neutrophils, normal platelet count, slightly elevated
creatinine level 152 mol/l, and a normal calcium. Thyroid
function was normal. Tests for hepatitis B, C and lues were
negative. Antinuclear antibodies, rheumatoid factor, anti-
neutrophil cytoplasmic antibodies and antiphospholipid
antibodies were absent. A chest radiogram and a computer
tomography of the abdomen revealed no abnormalities.
A skin biopsy revealed lymphocytic as well as neutrophilic
inflammation. Moreover, the biopsy showed plasma cells,
necrosis and re-epithelialisation. Vasculitis was absent in
the biopsy. 
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Table 1
Diseases associated with pyoderma gangrenosum
INFLAMMATORY BOWEL DISEASE 
(Chronic) ulcerative colitis
Crohn’s disease
Diverticular disease
Regional enteritis
ARTHRITIS 
Seronegative with inflammatory bowel disease 
Seronegative without inflammatory bowel disease
Rheumatoid arthritis
Spondylarthropathy 
HAEMATOLOGICAL DISEASE 
(Acute and chronic) myelocytic leukaemia 
Monoclonal gammopathy (IgA)
Hairy cell leukaemia
Myelofibrosis
Polycythaemia rubra vera
Lymphoma: Hodgkin’s disease, non-Hodgkin’s disease, cutaneous 
T cell 
IMMUNE ABNORMALITIES
Humoral Congenital and acquired 
hypogammaglobulinaemia
Selective, complete and 
hyperimmunoglobulin E syndrome
Streaking leucocyte factor
Cell-mediated Defective neutrophil function: 
reduced chemotaxis and impaired 
phagocytosis and oxygen uptake, 
aberrant neutrophil trafficking
Abnormal monocyte function
Abnormal response to skin antigens
Congenital deficiency in leucocyte-
adherence glycoproteins
Immunodeficiency/immunosuppression
SOLID TUMOURS ASSOCIATED WITH PG
Colon, bladder, prostate, breast, bronchus, ovary, adenocortical 
carcinoma
DRUGS TRIGGERING PG
Alpha 2b-interferon
OTHERS
Chronic active hepatitis, cryoglobulinaemia and hepatitis C, thyroid
disease, pulmonary disease, hidradenitis suppurativa, acne conglobata,
sarcoidosis, atrophic gastritis, diabetes mellitus, systemic lupus
erythematosus, Takayasu’s arteritis, dermatomyositis, HIV,
Wegener’s granulomatosis, sensorineuronal deafness, paroxysmal
nocturnal haemoglobinuria, peripheral ulcerative keratitis, lung 
injury, primary biliary cirrhosis
Initially a definitive diagnosis could not be made. During
a multidisciplinary meeting, however, one of the specialists,
to whom the lesions were shown, immediately considered
the diagnosis pyoderma gangrenosum on clinical grounds.
Further laboratory analysis, i.e. serum protein electropho-
resis, showed an IgG- paraproteinaemia. To see whether
there was a systemic skeletal involvement additional
radiograms were performed, without signs of multiple
myeloma. Moreover, neither cytology nor histology of the
bone marrow showed a localisation for multiple myeloma.
The ulcers of both legs started to heal within a week after
treatment with prednisolone 1 mg/kg was initiated
(figure 1B). Altogether, the presence of the monoclonal
gammopathy and the improvement of the lesions after
treatment were consistent with PG.
D I S C U S S I O N
Pyoderma gangrenosum in association with IgG- para-
proteinaemia is uncommon.10-12 Although the association
with monoclonal IgA gammopathy is well recognised,
multiple myeloma is rarely found. Also in our patient, we
could not find signs of systemic skeletal involvement. 
The conditions that may mimic ulcerative PG are systemic
vasculitis, dermatitis artefacta, infection (mycobacterial,
atypical mycobacterial, amebiasis, syphilis, herpes simplex,
deep fungal infection), drug reactions (hydroxyurea), insect
bite (spider), synergistic gangrene, antiphospholipid syn-
drome and cutaneous neoplasma (table 2). PG is a diagnosis
of exclusion, so the above-mentioned conditions should
be ruled out before the diagnosis of PG is made. Weenig
et al. have described that substantial misdiagnosis of skin
ulcers as PG can occur (approximately 10%).10
Misdiagnosis of PG can expose patients to risks associated
Simsek, et al. Pyoderma gangrenosum associated with IgG- paraproteinaemia.
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Figure 1
Ulcerative pyoderma gangrenosum before (A) and after
(B) treatment with steroids
Table 2
Differential diagnosis of pyoderma gangrenosum
ULCERATIVE PG 
Systemic vasculitis
Dermatitis artefacta
Infection: (atypical) mycobacterial, amebiasis, syphilis, herpes 
simplex (especially in HIV patients), deep fungal infections
Drug reactions (hydroxyurea)
Insect bite (spider)
Synergistic gangrene
Antiphospholipid syndrome
Cutaneous neoplasms
PUSTULAR PG 
Infection: bacterial, viral, fungal
Gonococcal septicaemia
Folliculitis
Pustular vasculitis
Pustular drug eruptions
Bowel bypass syndrome
Pyostomatitis vegetans
BULLOUS PG 
Atypical Sweet’s syndrome
Insect/arthropod bite
Viral infection (in immunocompromised patients)
Acute cellulitis
Bullous mycosis fungoides
Bullous dermatoses (erythema multiforme, etc.)
VEGETATIVE PG
Pyoderma vegetans
Blastomycosis-like pyoderma
Deep fungal infection
(Atypical) mycobacterial infection
Dermatitis artefacta
Cutaneous neoplasm
with its treatment. In that study, 95 patients appeared to
have skin ulcers caused by other diseases, although initially
PG was suspected. These causative diseases were vascular
occlusive or venous disease (such as antiphospholipid
syndrome, venous stasis ulceration and type I cryoglobu-
linaemia), vasculitis (among them Wegener’s granulomato-
sis, polyarteritis nodosa and cryoglobulinaemic (mixed)
vasculitis), cutaneous involvement of malignant process
(usually lymphoma), primary cutaneous infection (such
as deep fungal infection, herpes simplex virus type 2,
cutaneous tuberculosis), drug-induced or exogenous tissue
injury (among them Münchausen’s syndrome/factitial
disorder, hydroxyurea-induced ulceration). The authors thus
stress the need to follow a thorough diagnostic evaluation,
including collecting careful medical historical data, being
aware of characteristic features on physical examination,
performing a skin biopsy for not only histopathological
purposes but also for tissue culture, and ordering laboratory
investigations with the aim of ruling out diagnoses that
mimic PG (such as erythrocyte sedimentation rate, com-
plete blood count, blood chemistry, protein electrophoresis,
chest radiography, antiphospholipid, antinuclear, and
antineutrophil cytoplasmic antibodies). When PG is even-
tually established as the diagnosis, the patient should be
evaluated thoroughly to rule out other diagnoses after
long-term follow-up. 
However, in our patient, the opposite of what Weenig et al.
described in their study population happened. Namely, it
took rather a long time before a definitive diagnosis of PG
was made, due to the other possible causes of the ulceration. 
Skin biopsies in all forms of PG are characterised by a
central necrosis accompanied by a massive peripheral
neutrophilic infiltration and perivascular and intramural
lymphocytic infiltrates.13 A possible pathogenetic
mechanism underlying the association between PG and
monoclonal gammopathy could be the defective monocyte
function, as was suggested by Norris et al.14 and Jones et
al.12 Other possible mechanisms include abnormality of
neutrophil and monocyte chemotaxis, phagocytosis
(including defective leucocyte adhesion glycoproteins),
mast cell activation, hypogammaglobulinaemia or associ-
ation with hyperimmunoglobulinaemia E.5,13 Crowson
et al. mention in their review article that the pathogenetic
mechanism and the initial trigger are dependent on the
associated/underlying systemic disease, eventually leading
to the endpoint of a neutrophilic dermopathy with diverse
destruction of the epidermis and the adnex.13
In conclusion, we report a patient with chronic ulcers of
both legs with a history of peripheral bypass surgery and
(cardio)vascular risk factors. Despite an extensive search
for an ischaemic aetiology, a rare diagnosis, pyoderma
gangrenosum associated with IgG- paraproteinaemia,
was found to be the cause of the lesions. This case illus-
trates that the diagnosis of pyoderma gangrenosum is not
easy: many specialists were involved before one of them
coined the possibility of a PG. Since the disease is rare,
recognition is difficult. Suspicion of PG should be raised
when ulcers are present on the lower legs that are painful
and symmetrical and for which there is no other obvious
explanation. A thorough diagnostic effort must be made
to reveal underlying disease when PG is diagnosed.
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A B S T R A C T
Drug-induced acute pancreatitis should be in the differential
diagnosis of acute abdomen occurring soon after initiation
of tuberculosis treatment and chemoprophylaxis. Isoniazid-
induced pancreatitis is potentially reversible; early recogni-
tion and drug withdrawal are warranted in the appropriate
clinical setting. We present a case of reversible acute pan-
creatitis after isoniazid treatment of genitourinary tubercu-
losis, followed by recurrence of pancreatitis 12 years later
when the patient received isoniazid again for pulmonary
tuberculosis. Isoniazid-induced pancreatitis, if highly
suspicious or confirmed with re-challenge test, mandates
permanent avoidance of the drug.
I N T R O D U C T I O N
Isoniazid has been used for treatment of Mycobacterium
tuberculosis for over 50 years. Although it was initially
considered to be free of serious side effects, the potential
adverse effect of isoniazid hepatotoxicity has now become
evident. Furthermore, as our experience with isoniazid
accumulates, there have been more reports of isoniazid-
induced pancreatitis in post-marketing surveillance. This
category of adverse effect, albeit less frequent than hepato-
toxicity, should be promptly recognised because develop-
ment of acute pancreatitis mandates drug withdrawal and
permanent isoniazid avoidance as illustrated in our case.
C A S E  R E P O R T
A 25-year-old Chinese patient with a history of systemic
lupus erythematosus presented with malaise and progres-
sive uraemic symptoms. There was no history of alcohol
abuse. Plasma creatinine was 18.0 mg/dl (normal range,
0.6 to 1.4 mg/dl). Urinary sediment was unremarkable
except for sterile pyuria. Advanced renal failure with
quiescent lupus nephritis was diagnosed, followed by
identification of acid-fast bacilli in the early morning urine.
Intermittent peritoneal dialysis was commenced after
Tenckhoff catheter insertion, together with implementation
of quadruple tuberculosis treatment consisting of isoniazid
200 mg daily (5.5 mg/kg/day), rifampicin, pyrazinamide
and ethambutol. 
The patient developed acute severe pain in the epigastrium
region three weeks after initiation of tuberculosis therapy,
before the scheduled date for continuous ambulatory
peritoneal dialysis training. Examination revealed diffuse
abdominal tenderness. His serum and peritoneal dialysate
amylase levels were 2071 U/l (normal range, 44-128 U/l)
and 1478 U/l, respectively. An erect chest radiograph
demonstrated right apical granuloma only. Abdominal
sonography and computed tomographic imaging showed
an oedematous pancreas, in the absence of biliary tract
disease. The clinical picture of acute pancreatitis resolved
with conservative management and withdrawal of isoniazid
therapy. There were no other identifiable causes of acute
pancreatitis.
Subsequent cadaveric kidney transplantation was compli-
cated by progressive allograft dysfunction secondary to
chronic rejection. Twelve years later, reactivation of tuber-
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C A S E  R E P O R T
Recurrent acute pancreatitis after isoniazid 
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culosis occurred with pulmonary involvement. When
isoniazid 200 mg daily, rifampicin and levofloxacin were
started, his plasma creatinine was 6.7 mg/dl with an
estimated glomerular filtration rate of 12 ml/min/1.73 m2. 
After three weeks of tuberculosis therapy, the patient
presented acutely with marked epigastric tenderness. The
serum amylase level rose from 429 U/l to 2100 U/l within
five days. He had been receiving prednisolone, cyclosporin
and azathioprine for more than ten years, and the serum
amylase levels were normal in between the two attacks.
Ultrasound imaging confirmed the clinical impression of
acute nonbiliary pancreatitis. Again, the pain resolved 72
hours after discontinuation of isoniazid, accompanied by
biochemical and radiological evidence of improvement. No
further bouts of pancreatitis were encountered thereafter. 
D I S C U S S I O N
Drug-related acute pancreatitis is uncommon.1 As always,
causal relationship based on anecdotal case report(s) has
been a matter of controversy. Theoretically, it should be
clearly documented that pancreatitis developed during
treatment with the implicated drug, was reversed by with-
drawal of the drug, and recurred when the drug was rein-
troduced.2
We have previously reported another end-stage renal disease
patient with isoniazid-induced pancreatitis, which was
supported by means of re-challenge test.1 In case of tuber-
culosis therapy, controlled re-challenge with the drug sus-
pected of causing pancreatitis is deemed necessary in view
of the limited range of drugs available for Mycobacterium
tuberculosis infection as well as the confounding drug
culprit rifampicin.3 Now considered the first-line essential
antituberculous drug, isoniazid should be included in all
tuberculosis treatment regimens unless contraindicated. 
According to the case reports in literature,1,4-9 acute pan-
creatitis associated with isoniazid develops within three
weeks after drug administration and consistently recurs,
with a much earlier onset, if re-challenged soon after reso-
lution of pancreatitis (table 1). The role of concurrent
rifampicin may not be directly contributory since this com-
plication has been documented in several cases of isoniazid
monotherapy (mostly chemoprophylaxis therapy).4,6,9
It remains unclear whether the reaction of isoniazid-
induced pancreatitis occurs in a dose-dependent manner or
in the setting of a hypersensitivity syndrome to isoniazid. 
Given the short time lapse (i.e. hours between re-challenge
and occurrence of pancreatitis (table 1), the latter is most
likely. The current case allows us to evaluate recurrence
of pancreatitis as isoniazid was re-introduced 12 years
after the initial episode. Irrespective of the mechanisms
of isoniazid-induced pancreatitis,1 the message here is
clear: isoniazid should be permanently avoided once it
has been documented to cause acute pancreatitis. 
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Table 1
Well-documented case reports of isoniazid-induced acute pancreatitis
REFERENCE SUBJECT ESRD DAILY DIAGNOSIS AMYLASE ONSET (DAY(S)) OF ONSET OF 
SEX/AGE TREATMENT IN SERUM PANCREATITIS AFTER PANCREATITIS AFTER
DOSE (MG) (U/L) START OF ISONIAZID RE-CHALLENGE 
4 F/43 - 300 Chemoprophylaxis, Not done 4 2 hours
sarcoidosis
5 M/31 - 300  Gastrointestinal 758 14 6 hours
tuberculosis
6 M/68 - 300 Urinary bladder 458 0.5 No re-challenge
treatment
1 M/31 + 300 Pulmonary tuberculosis, 1672 21 5 days
IgA nephropathy
7 M/80 + 300 Tuberculous spondylitis, 782 2 No re-challenge
ischaemic nephropathy
8 M/42 - 300 Tuberculous spondylitis 645 11 8 hours
9 F/28 - 300 Chemoprophylaxis 356 21 No re-challenge
Our case M/25 + 200 Genitourinary tubercu- 2071 21 21 days
report losis, systemic lupus 
erythematosus
ESRD = end-stage renal disease, F = female, M = male.
Chow, et al. Recurrent acute pancreatitis after isoniazid.
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The plain abdominal radiograph reveals what was suspected during the repeat physical examination: a caecal blow-out.
The radiograph shows gas around the pathologically distended caecal part of the colon, and gas collection anterior and
medial of the caecum.
The computed tomography (figure 2) confirmed this diagnosis, and caecal perforation with early peritonitis was found during
laparotomy. An ileocaecal resection was carried out. The postoperative course was complicated by multiple organ failure.
The patient was transferred to our intensive care unit. Despite fluid resuscitation, mechanical ventilation, vasopressor
and antimicrobial treatment, and renal replacement therapy, he died from refractory septic shock.
The cause of his diarrhoea was not established. In hospital populations, caecal perforation is a well-known complication
of Clostridium difficile toxin-mediated diarrhoea.1 Several infectious conditions have occasionally been associated with
diarrhoea, toxic megacolon and caecal perforation. These infections include bacteria (Salmonella spp, tuberculosis),
helminths (Schistosoma mansoni) and viruses (CMV). Besides, collagen-vascular diseases such as Wegeners’ granulomatosis
may occasionally cause a similar clinical pattern. Idiopathic colonic pseudo-obstruction (Ogilvie’s syndrome) may also
cause caecal blow-out.2
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Figure 2
Abdominal CT confirms the presence of gas outside the caecal lumen that is clearly distended
At the recent Convention for Internal Medicine (Internistendagen) in Maastricht on 22 and 23 April 2004, the Netherlands
Journal of Medicine awarded the following prizes: the best original article, best case report and best review published in
the Netherlands Journal of Medicine in 2003.
A jury consisting of Professor P.W. de Leeuw, Dr C. Gaillard and Dr W. Hart selected the following papers:
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The winner may choose one of the original prints of the graphic art published on the covers of this journal.
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